Structure Therapeutics Secures Phase III Funding After Low-Discontinuation Phase II Results
Meridian Small Cap Growth Fund highlighted Structure Therapeutics’ oral GLP-1 candidate after Phase II trials showed strong efficacy and a lower-than-expected discontinuation rate, leading to a capital raise funding Phase III. GPCR shares fell 25.59% over one month but rose 192.26% over 12 months, giving a $4.829 billion market cap.
1. Phase II Trial Outcomes and Capital Raise
Structure Therapeutics’ lead oral GLP-1 candidate achieved strong efficacy and a lower-than-expected discontinuation rate in Phase II trials, prompting a successful capital raise sufficient to fund Phase III development.
2. Fund Letter Recognition
Meridian Small Cap Growth Fund cited Structure Therapeutics as a top holding in its Q4 2025 letter, reflecting confidence in the company’s clinical progress within a small-cap portfolio that returned 0.90% net in the quarter.
3. Stock Performance and Valuation
GPCR shares closed at $68.36 on February 18, lost 25.59% over the last month but gained 192.26% in the past year, and the company holds a market capitalization of $4.829 billion.